Critically Examining Data Management in ADC Development and Research

Antibody Drug Conjugates (ADCs) are a class of therapeutics that utilizes the specificity of monoclonal antibody (mAB) to enable targeted drug delivery. With more than 180 ADCs currently in clinical trials, the ADC market is predicted to grow from $2-3 billion today to over $13 billion by 2026.

Despite their potential, ADC development faces unique challenges. Due to their molecular complexity, ADCs require a number of analytical techniques to characterize their structures, drug antibody ratios (DARs), and impurity profiles. Drawing conclusions from data that has been generated using an array of instruments with incompatible file formats is often burdensome and time-consuming. This whitepaper explores issues with analytical data generated throughout the ADC development process and recommends tools to improve analytical data management.